Evidence map›Paper›PMID 38422337›Full record

Observational studyJornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia2024

Overprescription of short-acting β2 agonists: reflections from the SABINA study in Brazil.

Martti Anton Antila, Adelmir Souza-Machado, Marcelo Gervilla Gregório, Álvaro A Cruz, Luciene Angelini, Maarten J H I Beekman, Gilmar Alves Zonzin, Marcelo Fouad Rabahi

Open access · diamondAbstract readObservational Study
In one paragraph

Observational study in Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Martti Anton Antila. Clínica de Alergia Martti Antila, Sorocaba (SP) Brasil.ORCID 0000-0002-7294-4188
Adelmir Souza-Machado. Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador (BA) Brasil.ORCID 0000-0002-1475-2663
Marcelo Gervilla Gregório. Clínica RespSono, São Bernardo do Campo (SP) Brasil.ORCID 0000-0002-2526-4606
Álvaro A Cruz. Fundação ProAR, Brasil.ORCID 0000-0002-7403-3871
Luciene Angelini. AstraZeneca, São Paulo (SP) Brasil.ORCID 0009-0000-8147-9671
Maarten J H I Beekman. AstraZeneca, The Hague, the Netherlands.ORCID 0000-0002-5978-9697
Gilmar Alves Zonzin. Centro Médico Santa Maria, Barra Mansa (RJ) Brasil.ORCID 0000-0001-7434-0372
Marcelo Fouad Rabahi. Faculdade de Medicina, Universidade Federal de Goiás, Goiânia (GO) Brasil.ORCID 0000-0002-4050-5906
Universidade Federal da Bahia · BRAstraZeneca (Brazil) · BRAstraZeneca (Netherlands) · NLCentro Universitário de Barra Mansa · BRCentro Universitário FEI · BRUniversidade de Sorocaba · BRUniversidade Federal de Goiás · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess prescription patterns for short-acting b2 agonists (SABAs) and other asthma medications in asthma patients treated by specialists and participating in the SABA use IN Asthma (SABINA) study in Brazil.

methodsThis was an observational, cross-sectional study conducted at five sites in different regions of Brazil. The primary endpoints were to record SABA prescriptions and obtain data on over-the-counter (OTC) SABA purchases at the pharmacy.

resultsData on 218 asthma patients were analyzed. Of those 218 patients, 80.3% were prescribed SABAs in addition to their maintenance therapy, with a mean of 11.2 SABA canisters in the previous 12 months. Of those patients, 71.4% were prescribed ≥ 3 canisters and 42.2% were prescribed ≥ 10 canisters. None of the patients were prescribed SABA monotherapy. A total of 14.2% of the patients reported purchasing SABAs OTC at a pharmacy without a prescription. Of those, 48.4% purchased ≥ 3 SABA canisters. A fixed-dose combination of an inhaled corticosteroid and a long-acting b2 agonist was prescribed to 95.0% of the patients. In the year before the study visit, 45.0% of the patients received at least one course of oral corticosteroid burst treatment. Asthma was well controlled in 43.1% of the patients, partly controlled in 34.9%, and uncontrolled in 22.0%. Patients reported a mean of 1.1 severe asthma exacerbations, with 49.1% experiencing 1 or more severe exacerbations.

conclusionsOverprescription and OTC purchases of SABAs are common in Brazil, possibly leading to the need for courses of oral corticosteroids. The health care community should collaborate to implement evidence-based recommendations and promote health education to improve asthma management in Brazil.

Indexed as

AsthmaHealth PromotionAdrenal Cortex HormonesBrazilCross-Sectional StudiesDelivery of Health CareHumansAdrenal Cortex Hormones

Identifiers

PMID38422337
PMCPMC11095926
OpenAlexW4390942268

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.